Please login to the form below

Not currently logged in
Email:
Password:

Merck & Co prepares to file first-in-class insomnia drug for US approval

Will submit orexin receptor antagonist suvorexant to the FDA later this year

Merck & Co is planning to submit its potential first-in-class insomnia treatment suvorexant for US approval later this year.

If approved suvorexant would enter a US sleep drug market worth an estimated $2bn in 2010, with sales led by Sanofi's Ambien CR and Sunovion's Lunestra.

Two phase III trials of the orexin receptor antagonist suvorexant have been completed and the company said they show positive results.

"Suvorexant selectively targets an important pathway involved in helping to promote sleep and, if approved, will be a new, first-in-class treatment for patients with insomnia," said Peter Kim, president, Merck Research Laboratories.

"We are enthusiastic about the potential of this investigational medicine, and look forward to sharing the results from these studies with the medical community."

The primary endpoint for the trials was change from baseline in subjective total sleep time and time to sleep onset, wake time after persistent sleep onset, and latency to onset of persistent sleep at one and three months.

Merck plans to present data from the studies at medical meetings later this year.

Suvorexant is one of five major US filings the company hopes to make in 2012 and 2013, along with neuromuscular reversal agent Bridion (sugammadex), HPV vaccine V503, osteoporosis treatment odanacatib and atherosclerosis medicine Tredaptive ER.

7th February 2012

Share

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Accession

Accession was a born from a passion and a vision. A passion to harness the power of market access to...

Latest intelligence

Flu
Influenza – the risk to vulnerable populations
Why we can't get complacent about flu vaccination...
dementia
Alzheimer’s Research UK highlights socio-economic inequalities in dementia risk
The charity aims to improve the number of women participating in dementia research and grow awareness of dementia risk factors...
Data security
Concerns about data security are building a strong case for clinical mobility in EMEA
Electronic medical records have transformed the storage of sensitive information but how can the healthcare sector continue to protect patient and staff data?...